Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-27
2007-02-27
McKane, Josph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S270400, C546S271700, C546S273400
Reexamination Certificate
active
11407076
ABSTRACT:
A compound represented by the following formula (1):(wherein each of R1and R2, which may be identical to or different from each other, represents a hydrogen atom, a methyl group, or an ethyl group; each of R3a, R3b, R4a, and R4b, which may be identical to or different from each other, represents a hydrogen atom, a halogen atom, a nitro group, a hydroxyl group, a C1-4alkyl group, a trifluoromethyl group, a C1-4alkoxy group, a C1-4alkylcarbonyloxy group, a di-C1-4alkylamino group, a C1-4alkylsulfonyloxy group, a C1-4alkylsulfonyl group, a C1-4alkylsulfinyl group, or a C1-4alkylthio group, or R3aand R3b, or R4aand R4bmay be linked together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5(R5represents a hydrogen atom, a C1-4alkyl group, a C1-4alkylsulfonyl group, or a C1-4alkyloxycarbonyl group); Y represents an oxygen atom, S(O)l(l is a number of 0 to 2), a carbonyl group, a carbonylamino group, an aminocarbonyl group, a sulfonylamino group, or an aminosulfonyl group; Z represents CH or N; n is a number of 1 to 6; and m is a number of 2 to 6) or a salt thereof; and therapeutic drugs containing any of such a compound or salt.
REFERENCES:
patent: 6653334 (2003-11-01), Yamazaki et al.
patent: WO 97/28149 (1997-08-01), None
patent: WO 02/46176 (2002-06-01), None
Isabelle Issemann et al., “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators”,NATURE, vol. 347, pp. 645-650., Oct. 18, 1990.
Christine Dreyer, et al., “Control of the Peroxisomal β-Oxidation Pathway by a Novel Family of Nuclear Hormone Receptors”,CELL, vol. 68, pp. 879-887, Mar. 6, 1992.
Letter to the Editor, “A Unified Nomenclature System for the Nucleur Receptor Superfamily”,CELL, vol. 97, pp. 161-163, Apr. 16, 1999.
Kristina Schoonjans, et al., “The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation”,Biochimica et Biophysica Acta, vol. 1302, pp. 93-109. (1996).
Timothy M. Willson, et al., “The PPARs: From Orphan Receptors to Drug Discovery”,Journal of Medicinal Chemistry, vol. 43, No. 4, pp. 527-550. Feb. 24, 2000.
Frank J. Gonzalez, et al., “Mechanism of Action of the Nongenotoxic Peroxisome Proliferators: Role of the Peroxisome Proliferator-Activated Receptor α”,Journal of the National Cancer Institute. vol. 90, No. 22, Nov. 18, 1998.
Jean-Charles Fruchart, et al., “Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atheroscierosis”,Current Opinion in Lipidology, vol. 10, pp. 245-257 (1999).
Johan Auwerx, et al., “Regulation of Triglyceride Metabolism by PPARs: Fibrates and Thiazolidinediones have Distinct Effects”,Journal of Atherosclerosis and Thrombosis, vol. 3, No. 2, pp. 81-89. (1996).
Bart Staels, et al., “Role of PPAR in the Pharmacological Regulation of Lipoprotein Metabolism by Fibrates and Thiazolidinediones”,Current Pharmaceutical Design. vol. 3, pp. 1-14. (1997).
Inés Pineda Torra, et al., “Peroxisome proliferator-activated receptor alpha in metabolic disease, Inflammation, atherosclerosis and aging”,Current Opinion in Lipidology, vol. 10, pp. 151-159, (1999).
Joseph Vamecq, et al., “Medical significance of peroxisome proliferator-activated receptors”,The Lancet, vol. 354, pp. 141-148, Jul. 10, 1999.
Sander J. Robins, “PPARα ligands and clinical trials: cardiovascular risk reduction with fibrates”,Journal of Cardiovascular Risk, vol. 8, pp. 195-201. (2001).
Jürgen M. Lehmann, et al., “An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)”, The Journal of Biological Chemistry, vol. 270, No. 22, pp. 12953-12956. (1995).
Joel Berger, et al., “Thiazolidinediones Produce a Conformational Change in Peroxisomal Proliferator-Activated Receptor-γ: Binding and Activation Correlate with Antidiabetic Actions in db/db Mice”,Endocrinology, vol. 137, No. 10, pp. 4189-4195, (1996).
Mauricio Reginato, et al., “Mechanisms by which Thiazolidinediones Enhance Insulin Action”,TEM, vol. 10, No. 1, pp. 9-13. (1999).
Akira Okuno, et al., “Troglitazone Increases the Number of Small Adipocytes Without the Changes of White Adipose Tissue Mass in Obese Zucker Rats”,J. Clin Invest., vol. 101, No. 6, pp. 1354-1361, Mar. 1998.
Naoki Sakane, et al., “Glitazones and NIDDM”,The Lancet, vol. 349, pp. 952, Mar. 29, 1997.
Jennifer L. Oberfield, et al., “A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation”,Proc. Natl. Acad. Sci USA, vol. 96, pp. 6102-6106, May 1999.
Harold M. Wright et al., “A Synthetic Antagonist for the Peroxisome Proliferator-activated Receptor γ Inhibits Adipocyte Differentiation”,The Journal of Biological Chemistry, vol. 275, No. 3, pp. 1873-1877. (2000).
Toshimasa Yamauchi, et al., “Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes”,The Journal of Clinical Investigation, vol. 108, No. 7, pp. 1001-1013, Oct. 2001.
Didier Auboeuf, et al., “Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator-Activated Receptors and Liver X Receptor-α in Humans, No Alteration in Adipose Tissue of Obese and NIDDM Patients”,Diabetes, vol. 46, pp. 1319-1327, Aug. 1997.
William R. Oliver, Jr., et al., “A selective peroxisome proliferator-activated receptor δ agoinst promotes reverse cholesterol transport”,PNAS, vol. 98, No. 9, pp. 5306-5311, Apr. 24, 2001.
Yong-Xu Wang, et al., “Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity”,Cell, vol. 113, pp. 159-170, Apr. 18, 2003.
Helen Vosper, et al., “The Peroxisome Proliferator-activated Receptor δ Promotes Lipid Accumulation in Human Macropages”,The Journal of Biological Chemistry, vol. 276, No. 47, pp. 44258-44265. (2001).
Yaacov Barak, et al., “Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer”,PNAS, vol. 99, No. 1, pp. 303-308, Jan. 8, 2002.
Abe Kazutoyo
Araki Takaaki
Nishikawa Masahiro
Oda Soichi
Okuda Ayumu
Barker Michael
Kowa Co. Ltd.
McKane Josph K.
LandOfFree
PPAR-activating compound and pharmaceutical composition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PPAR-activating compound and pharmaceutical composition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PPAR-activating compound and pharmaceutical composition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3825699